PD52-02 HUMAN VOLATILOME ANALYSIS OF PATIENTS WITH RENAL CELL CARCINOMA: PROSPECTIVE, TWO-ARM NON-RANDOMIZED MONOCENTRIC STUDY (2021)

You have accessJournal of UrologyKidney Cancer: Epidemiology & Evaluation/Staging/Surveillance II (PD52)1 Sep 2021PD52-02 HUMAN VOLATILOME ANALYSIS OF PATIENTS WITH RENAL CELL CARCINOMA: PROSPECTIVE, TWO-ARM NON-RANDOMIZED MONOCENTRIC STUDY Alessio Filianoti, Manuela Costantini, Umberto Anceschi, Alfredo Maria Bove, Aldo Brassetti, Maria Consilia Ferriero, Riccardo Mastroianni, Leonardo Misuraca, Gabriele Tuderti, Gennaro Ciliberto, and Giuseppe Simone Alessio FilianotiAlessio Filianoti More articles by this author , Manuela CostantiniManuela Costantini More articles by this author , Umberto AnceschiUmberto Anceschi More articles by this author , Alfredo Maria BoveAlfredo Maria Bove More articles by this author , Aldo BrassettiAldo Brassetti More articles by this author , Maria Consilia FerrieroMaria Consilia Ferriero More articles by this author , Riccardo MastroianniRiccardo Mastroianni More articles by this author , Leonardo MisuracaLeonardo Misuraca More articles by this author , Gabriele TudertiGabriele Tuderti More articles by this author , Gennaro CilibertoGennaro Ciliberto More articles by this author , and Giuseppe SimoneGiuseppe Simone More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002079.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Urine analysis by electronic (e)-nose technology provides volatile organic compounds (VOCs) molecular profiles that have shown potential in the diagnosis of non-urological diseases. Few works suggested that dogs trained to smell urine could recognize lung, bladder, or breast cancer with various success rates, but no date are available in the diagnostic setting of renal cell carcinoma (RCC). In this study, we investigated the diagnostic potential of urinary VOCs profiling in discriminating patients with established diagnosis of RCC from healthy controls. METHODS: This prospective study included 2 groups: 115 healthy controls (HC) and 98 RCC cases. Urine samples were collected twice and then sampled by a commercially electronic nose (Cyranose C320 – 32 sensors). Data were reduced to a set of principal components capturing the largest amount of variance of the original 32 sensors (Principal components analysis [PCA]). Univariate analysis of variance was used to select the best discriminating components to be entered into a linear Canonical Discriminant Analysis (CDA) to classify cases into a categorical partition. We used the “leave-one-out method” to calculate the Cross Validated Accuracy (CVA), an estimate of accuracy of a predictive model in clinical practice. For each case the probability of a positive diagnosis was calculated on basis of the CDA function. Discrimination accuracy of the built model was evaluated by means of receiver operator characteristics (ROC) curves. RESULTS: Based on PCA, 83/98 and 99/115 cases were correctly identified by eNose in the RCC and healthy controls arms, respectively. Results obtained with CDA demonstrated correct classification in 85.4% of cases (p <0.001). At ROC analysis discrimination accuracy between RCC patients and healthy controls was 0.907. Repeated analysis using the second measure of each collected urine sample provided comparable findings (CVA 85.1% and ROC-curve of 0.89). Sensitivity and specificity were 84.7% and 86.1, respectively; positive likelihood ratio (+LR) and negative likelihood ratio (-LR) were 6.09 and 0.18, respectively. CONCLUSIONS: Preliminary findings of this pilot study highlights potential for future research in the diagnostic setting of RCC using eNose. Ease of use, low costs and non-invasive nature makes this test a potential biomarker in different diagnostic settings, from diagnosis to follow-up. Source of Funding: NONE © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e911-e911 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Alessio Filianoti More articles by this author Manuela Costantini More articles by this author Umberto Anceschi More articles by this author Alfredo Maria Bove More articles by this author Aldo Brassetti More articles by this author Maria Consilia Ferriero More articles by this author Riccardo Mastroianni More articles by this author Leonardo Misuraca More articles by this author Gabriele Tuderti More articles by this author Gennaro Ciliberto More articles by this author Giuseppe Simone More articles by this author Expand All Advertisement Loading ...